Skip to main content

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Resources
Contact
Double Check Campaign
Logout

Boehringer Ingelheim

FACE IPF

HEAD ON

and modify disease progression by slowing lung function decline

banner

How to understand and manage limited cutaneous SSc-ILD

19/06/2024 | Author: Boehringer Ingelheim

Document ID: PC-SA-102498 | Expiry Date: 29/05/2026

New PPF Guidelines

How to understand and manage limited cutaneous SSc-ILD

Safety Profile of OFEV

Treatment of patients with PPF and CTD-ILD

How to recognize ILD and PPF in patients with CTD

The Need to Act in the Face of Progression

How to identify patients with RA-ILD who can benefit from OFEV

RELATED CONTENT

How to identify patients with RA-ILD who can benefit from OFEV

PDF

How to identify patients with RA-ILD who can benefit from OFEV

PC-KW-100729 (October 2026 )

Download Opens in new tab

The Need to Act in the Face of Progression

PDF

The Need to Act in the Face of Progression

PC-KW-100734 (November 2026 )

Download Opens in new tab

How to recognize ILD and PPF in patients with CTD

PDF

How to recognize ILD and PPF in patients with CTD

PC-KW-100728 (May 2026 )

Download Opens in new tab

Treatment of patients with PPF and CTD-ILD

3:43

Treatment of patients with PPF and CTD-ILD

PC-KW-100730 (May 2026 )

Watch now Opens in new tab

PDF

Safety Profile of OFEV

PC-SA-102493 (May 2026 )

Download Opens in new tab

Home
OFEV
How to understand and manage limited cutaneous SSc-ILD

Boehringer Ingelheim

Site Map
Privacy
Terms of use
Contact

.

© 2010-2023 Boehringer Ingelheim International GmbH. All rights reserved. PC-KW-100660